

Table S-1. Clinical features of CHB patients with HBsAg seroclearance.

Variable	No. of patients (%)/ median (interquartile range)
Gender	
Male	47 (82.46)
Female	10 (17.54)
Age (years)	37.42 (30.20, 46.09)
BMI (kg/m ²)	22.96 (19.88, 26.23)
History of alcohol intake	
Yes	11 (19.30)
Family history of HBV	
Yes	27 (47.37)
Family history of HCC	
Yes	5 (8.77)
AST (U/L)	32.00 (24.00, 45.50)
ALT (U/L)	29.00 (20.00, 47.50)
Albumin (g/L)	46.70 (44.55, 48.40)
HBV DNA log ₁₀ (IU/ml)	0 (0, 3.33)
qHBsAg log ₁₀ (IU/ml)	1.76 (0.39, 3.22)
HBeAg status	
Positive	7 (12.28)
Negative	50 (87.72)
Antiviral treatment	33 (57.89)
Nucleoside/nucleotide analogue	28 (49.12)
Interferon	2 (3.51)
Nucleoside/nucleotide analogue+Interferon	3 (5.26)
No antiviral treatment	24 (42.11)
HBeAg clearance	2 (3.51)
HBeAg seroconversion	10 (17.54)
Follow-up time (months)	56.83 (35.60, 74.10)

Abbreviations: CHB: Chronic Hepatitis B; BMI: Body Mass Index; HBV: Hepatitis B Virus; HCC: Hepatocellular Carcinoma; ALT: alanine aminotransferase; AST: aspartate aminotran-

sferase; HBV DNA: Hepatitis B Viral Deoxyribonucleic acid load at baseline; qHBsAg: quantitative hepatitis B surface antigen; HBeAg: Hepatitis B e-antigen.